Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to $92.1 million.

  • Karyopharm Therapeutics' Total Current Liabilities fell 22.11% to $92.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $92.1 million, marking a year-over-year decrease of 22.11%. This contributed to the annual value of $92.1 million for FY2025, which is 22.11% down from last year.
  • Per Karyopharm Therapeutics' latest filing, its Total Current Liabilities stood at $92.1 million for Q4 2025, which was down 22.11% from $87.2 million recorded in Q3 2025.
  • Over the past 5 years, Karyopharm Therapeutics' Total Current Liabilities peaked at $99.2 million during Q2 2025, and registered a low of $57.6 million during Q2 2024.
  • For the 5-year period, Karyopharm Therapeutics' Total Current Liabilities averaged around $70.8 million, with its median value being $65.6 million (2022).
  • In the last 5 years, Karyopharm Therapeutics' Total Current Liabilities plummeted by 1059.44% in 2022 and then skyrocketed by 7219.32% in 2025.
  • Quarter analysis of 5 years shows Karyopharm Therapeutics' Total Current Liabilities stood at $73.7 million in 2021, then fell by 10.59% to $65.9 million in 2022, then rose by 5.42% to $69.5 million in 2023, then surged by 32.79% to $92.3 million in 2024, then fell by 0.22% to $92.1 million in 2025.
  • Its last three reported values are $92.1 million in Q4 2025, $87.2 million for Q3 2025, and $99.2 million during Q2 2025.